Literature DB >> 30170918

Contemporary management of patients referring to cardiologists one to three years from a myocardial infarction: The EYESHOT Post-MI study.

Leonardo De Luca1, Federico Piscione2, Furio Colivicchi3, Donata Lucci4, Franco Mascia5, Barbara Marinoni6, Plinio Cirillo7, Daniele Grosseto8, Ciro Mauro9, Paolo Calabrò10, Federico Nardi11, Roberta Rossini12, Giovanna Geraci13, Domenico Gabrielli14, Andrea Di Lenarda15, Michele Massimo Gulizia16.   

Abstract

AIMS: To describe the contemporary management by cardiologists of patients after an episode of myocardial infarction (MI).
METHODS: The EYESHOT Post-MI was a prospective, observational, nationwide study aimed to evaluate the management of patients referring to cardiologists 1 to 3 years from the last MI event.
RESULTS: Over a 3-month period, 1633 consecutive patients [median 22 (IQR 15-28) months from MI] were enrolled: 1028 (63.0%) at the second and 605 (37.0%) at the third year from MI. During the 12 months prior to enrolment, the majority of patients received a transthoracic echocardiogram (60% and 54%), followed by coronary angiography (24% and 16%, in the second and third year from MI groups, respectively). At the time of enrolment, the majority of patients were prescribed on statins (93%) and beta-blockers (82%), without significant differences between the 2 groups. A dual antiplatelet therapy (DAPT) was used more frequently among patients presenting during the second compared to the third year from MI (40% vs 24%; p < 0.0001). At multivariable analysis, the time interval from last MI (2 vs 3 years: OR 2.27; 95% CI 1.79-2.88; p < 0.0001) and a previous percutaneous coronary intervention with multiple stents (OR 3.46; 95% CI 2.19-5.47; p < 0.0001) resulted as the major independent predictors of DAPT persistence at the time of enrolment.
CONCLUSIONS: This contemporary registry provides unique insights into the current management of post-MI patients and represents an opportunity to further improve the long-term treatment of this high-risk population.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clopidogrel; Dual antiplatelet therapy; Percutaneous coronary intervention; Post-MI; Secondary prevention; Ticagrelor

Mesh:

Substances:

Year:  2018        PMID: 30170918     DOI: 10.1016/j.ijcard.2018.08.055

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

Review 1.  Antithrombotic Therapy in Patients with Coronary Artery Disease and Prior Stroke.

Authors:  Elisa Bellettini; Leonardo De Luca
Journal:  J Clin Med       Date:  2021-04-29       Impact factor: 4.241

2.  How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study.

Authors:  Leonardo De Luca; Furio Colivicchi; Jennifer Meessen; Massimo Uguccioni; Federico Piscione; Paola Bernabò; Gerardina Lardieri; Antonino Granatelli; Domenico Gabrielli; Michele M Gulizia
Journal:  Clin Cardiol       Date:  2019-08-31       Impact factor: 2.882

3.  Prolonged double antiplatelet therapy vs association of antiplatelet and low dose of anticoagulant therapy: PEGASUS or COMPASS?

Authors:  Natale Daniele Brunetti; Luisa De Gennaro; Matteo Di Biase; Pasquale Caldarola
Journal:  Int J Cardiol Heart Vasc       Date:  2019-07-16

4.  Incidence, Characteristics, and Management of Patients with Recurrent Myocardial Infarctions: Insights from the EYESHOT POST-MI.

Authors:  Leonardo De Luca; Furio Colivicchi; Domenico Gabrielli; Donata Lucci; Gabriele Grippo; Francesco Piemonte; Bruno Villari; Andrea Di Lenarda; Fabrizio Oliva; Michele Massimo Gulizia
Journal:  J Interv Cardiol       Date:  2022-03-18       Impact factor: 2.279

5.  Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries.

Authors:  Furio Colivicchi; Michele Massimo Gulizia; Marcello Arca; Pier Luigi Temporelli; Lucio Gonzini; Vanessa Venturelli; Nuccia Morici; Ciro Indolfi; Domenico Gabrielli; Leonardo De Luca
Journal:  Cardiovasc Ther       Date:  2020-01-03       Impact factor: 3.023

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.